Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- CLS +13%, CALX +11%, IBM +8.1%, NOK +7.7%, OSK +7.7%, LVS +6.6%, LRCX +5.5%, FLG +5.4%, WDC +4.6%, MTH +4.5%, LAZ +4.3%, NFG +3.7%, CHKP +3.5%, SEIC +3.4%, BHE +3%, TAK +2.9%, PHM +2.9%, DOV +2.9%, SNY +2.8%, MBUU +2.7%, TWO +2.4%, ROP +2.2%, MMC +2.1%, BX +1.7%, TSLA +1.6%, AMP +1.4%, NLY +1.2%, CCS +1.2%, LSTR +1.2%, RES +1.2%, META +1.1%, SHEL +1.1%, CNX +1.1%, CP +0.9%, WM +0.9%, LHX +0.9%, RCI +0.8%
Other news:
- TECX +40% (interim data from the Phase 1b acute hemodynamic clinical trial of its lead product candidate, TX45)
- VBTX +23.3% (CFO to retire; names new CFO)
- OFG +18.9% (increases dividend)
- MXCT +4.7% (acquires SeQure Dx)
- LAES +3.7% (expands its patent pool)
- PESI +2.7% (names new COO)
- STGW +2.6% (launches STAGE AI)
- COUR +1.8% (CEO to retire, names new CEO)
- ALLY +1.5% (CEO bought $1 mln in shares)
- BALL +1.2% (authorizes new $4 bln share repurchase program)
- UTL +1.2% (increases dividend)
- CLMB +1.1% (names new chairman)
- IIPR +1.1% (reached an agreement with PharmaCann Inc. and its affiliates to resolve PharmaCann's existing defaults under leases for eleven properties that the Company owns, previously announced by IIP on December 20, 2024)